BioCentury
ARTICLE | Financial News

Protein misfolding play Orphazyme prices IPO

November 16, 2017 10:01 PM UTC

Protein misfolding company Orphazyme A/S (CSE:ORPHA TEMP) was unchanged on Thursday after it debuted on NASDAQ Copenhagen, raising DKK 600 million ($94.1 million) in an IPO through the sale of 7.5 million shares at DKK 80. Investors included SEB, Vækstfonden, BankInvest, Handelsbanken, Spar Nord, Novo Holdings A/S (Hellerup, Denmark), Aescap Venture, Sunstone Capital, LSP, the ALS Investment Fund, Idinvest Partners and Kurma Partners.

Orphazyme is evaluating lead candidate arimoclomol in separate Phase II/III trials to treat sporadic inclusion body myositis (sIBM) and Niemann-Pick disease type C (NPC), and plans to start an additional Phase II/III trial in amyotrophic lateral sclerosis (ALS) in 2H18. The company intends to complete all three Phase II/III trials by the end of 2020. The small molecule inducer of heat shock protein 70 (Hsp70) is also in Phase I testing to treat Gaucher disease, with a Phase II trial expected to begin next year...

BCIQ Company Profiles

Novo Holdings A/S

Orphazyme A/S

BCIQ Target Profiles

Heat shock protein 70 (Hsp70)